A phase 4, single-arm, open-label treatment, descriptive study of upadacitinib effectiveness assessed by magnetic resonance imaging (MRI) changes in the hand/wrist and clinical response outcomes in participants with rheumatoid arthritis on methotrexate and who are biologic nave.
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Upadacitinib (Primary)
- Indications Rheumatoid arthritis; Synovitis
- Focus Therapeutic Use
Most Recent Events
- 11 Apr 2022 Planned End Date changed from 31 Mar 2023 to 30 Oct 2023.
- 11 Apr 2022 Planned initiation date changed from 1 Mar 2022 to 2 May 2022.
- 14 Mar 2022 New trial record